MULTINOIR’s comprehensive formulation targets cellular health through multifaceted mechanisms. Vitamin A, a key lipophilic micronutrient, is integral to these processes, supporting cell differentiation, immune function, and epithelia integrity.
A randomized, placebo-controlled trial is currently underway in Malaysia, investigating the efficacy of weekly vitamin D₃ supplementation (50,000 IU/wk) in improving insomnia symptoms and sleep quality among vitamin D-deficient women aged 19-50 years. As of July 2026, 33 eligible participants with serum 25(OH)D levels <20 ng/mL and insomnia have been enrolled, with 22 having completed the 9-week intervention phase. Primary outcomes include Insomnia Severity Index (ISI) and Pittsburgh Sleep Quality Index (PSQI), alongside objective actigraphy for sleep efficiency, with secondary outcomes assessing daytime sleepiness and functional impact. Participant recruitment commenced in December 2023 and is expected to conclude in December 2026.
The aforementioned study highlights the profound impact specific micronutrients can have on systemic health, underscoring the critical importance of a balanced nutritional status. While MULTINOIR is not indicated for insomnia, its comprehensive formulation, including Vitamin A, is strategically designed to support cellular vitality across its approved indications. Vitamin A, as a key component of MULTINOIR’s antioxidant complex, contributes to preventing oxidative damage in chronic conditions and supporting the structural integrity of tissues, including those in the eyes and nails, thereby assisting in the healthy maintenance of these systems. This foundational support helps individuals maintain baseline health where nutritional deficiencies contribute to compromised physiological function. The careful dosage of Vitamin A within MULTINOIR is formulated to provide therapeutic benefit while strictly adhering to established safety parameters. It is crucial to note that MULTINOIR is contraindicated in patients with pre-existing hypervitaminosis A, and concomitant use with other Vitamin A derivatives, such as isotretinoin, must be avoided to prevent potential toxicity. Furthermore, patients with known hypersensitivity to fish oils or any excipients should not use MULTINOIR, and caution is advised for those concurrently taking anticoagulants due to potential minor interactions with Vitamin K and Omega-3s.
Q: What role does Vitamin A play in MULTINOIR’s dermatological and ophthalmic efficacy claims?
A: Vitamin A is vital for the proper differentiation and maintenance of epithelial tissues, which are fundamental components of healthy skin, nails, and the ocular surface, thereby directly supporting MULTINOIR’s claims for dermatological and ophthalmic health.
Q: Are there specific contraindications for MULTINOIR regarding Vitamin A?
A: Yes, MULTINOIR is contraindicated in patients with pre-existing hypervitaminosis A. Concomitant use with other Vitamin A derivatives, such as isotretinoin, should be strictly avoided to prevent potential Vitamin A toxicity.
